TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Improving the Sleep and Circadian Rhythms of Mechanically Ventilated Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Receiving mechanical ventilation and intravenous sedation~Exclusion Criteria:~* Debilitating central nervous system disease or degenerative disorder~* Active seizures~* Persistent coma~* Renal failure requiring dialysis~* Expected to be extubated within 24 hours~* Currently receiving neuromuscular blocker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sleep promotion protocol (Type: EXPERIMENTAL): Behavioral: 48 hours of sleep and circadian rhythm promotion including timed light exposure.
- Usual care (Type: ACTIVE_COMPARATOR): Behavioral: 48 hours of usual care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Patients who meet ALL the following criteria can be enrolled:~* Male or female aged at least 18 years.~* With a diagnosis of moderate-to-severe chronic plaque psoriasis. As per Belgian National Institute for Health and Disability Insurance (NIHDI), moderate-to-severe plaque psoriasis in adult patients is defined by a Body Surface Area (BSA) \> 10% or aPsoriasis Area and Severity Index (PASI) \> 10.~* For whom the treating dermatologist has made the decision to commence apremilast treatment in accordance with the local label and reimbursement criteria~* Able to follow the instructions of the study.~* Having signed an Informed Consent Form (ICF)~Exclusion Criteria:~Patients who meet AT LEAST one of the following exclusion criteria will be excluded:~* Patients who have received apremilast \> 4 weeks prior to the enrolment visit.~* Women who are pregnant, breastfeeding or planning on becoming pregnant.~* Non-menopausal women who are not using an adequate contraception method.~* Patients with hypersensitivity to apremilast or to one of its excipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Use of Apremilast in patient with plaque psoriasis (Type: None): Psoriasis patients treated with Otezla® (Apremilast) in Belgium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perianal Versus Endoanal Application of Glyceryl Trinitrate 0.4% Ointment for Chronic Anal Fissure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Before a definitive definition of chronic anal fissure and ensuring inclusion in the study, all patients diagnosed as having chronic anal fissure based on their medical history and physical exploration were treated for a minimum of six weeks with conservative medical treatment (high residue diet, analgesics, and warm sitz baths). Chronic anal fissure was defined by the presence of a fibrous induration or exposed internal sphincter fibres.~Exclusion Criteria:~* Associated anal pathologies (incontinence, stenosis, abscess, fistula and haemorrhoids)~* Patients with associated conditions (inflammatory bowel disease, acquired immunodeficiency syndrome, tuberculosis, sexually transmitted disease and immunosuppression)~* Cardiopathy~* Headache and pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Endoanal application
- 2 (Type: EXPERIMENTAL): Perianal application

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria for CBT or Peer Intervention Participants:~1. Female~2. Age 18-55~3. Did not inject drugs in the past 6 months~4. Self-reported sex with at least 1 male partner in the past 6 months~5. Had at least 1 of the following sexual risk factors:~   1. More than 2 sex partners in the past 6 months~  2. STI diagnosis in the past 6 months~  3. Had a high risk sex partner in the past 90 days (i.e. a sex partner that injected drugs, smoked crack, was HIV+, or MSM)~Inclusion Criteria for Peer Network Participants:~1. 18 years old or older~2. One of the following:~   1. Injected drugs~  2. Sex partner of index~  3. Social network member that the index felt comfortable talking to about HIV/STIs~Exclusion Criteria for All Participants:~* Currently enrolled in another HIV prevention intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- Intervention Condition: CHAT (Type: EXPERIMENTAL): Participants received the program over the course of five small group sessions and one individual session based on a harm reduction philosophy. Participants were trained as Peer Mentors and were encouraged to talk to their family, friends, and sex partners about a range of sex risk reduction options.
- Comparison Condition: Standard of Care (Type: ACTIVE_COMPARATOR): The comparison condition consisted of one group session. The session focused on HIV and STIs transmission and risk reduction information.
- Network Participants (Type: NO_INTERVENTION): Index participants generated a list of network members during their baseline visits and were asked to recruit eligible network members into the study. These network participants completed study interviews but did not participate in the intervention.
- Non-randomized Baseline index participants (Type: NO_INTERVENTION): This arm includes those index participants that did not show up for randomization or did not recruit a network member were thus not eligible to be randomized into a study condition.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of CD55-deficient PLE/CHAPLE disease (based on a history of PLE), confirmed by biallelic CD55 loss-of-function mutation detected by genotype analysis~* Active disease as defined by the protocol or inactive disease on eculizumab therapy (and whose treating physician has the expectation of future access to renewed eculizumab treatment should this be required), and is willing to discontinue eculizumab during screening and start pozelimab at baseline with no eculizumab wash-out~Key Exclusion Criteria:~* History of meningococcal infection~* No documented meningococcal vaccination within 3 years prior to screening and patient unwilling to undergo vaccination during the study~* No documented vaccination for Haemophilus influenzae and Streptococcus pneumoniae if applicable based on local practice or guidelines prior to screening and patient unwilling to undergo vaccination during the study if required per local practice or guidelines~* Presence of a concomitant disease that leads to hypoproteinemia at the time of starting pozelimab~* A concomitant disease that leads to secondary intestinal lymphangiectasia such as a fontan procedure for congenital heart disease~Note: Other protocol-defined Inclusion/Exclusion criteria apply.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active PLE (Type: EXPERIMENTAL): Patients aged 1 year and older with a clinical diagnosis of CD55-deficient PLE disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia or schizophreniform disorder;~* Duration of symptoms not longer than 60 months;~* No prior treatment with antipsychotic medication or, if previously treated, a total lifetime usage of less than 14 days;~* Between 16 and 40 years of age; and~* Current psychotic symptoms of moderate severity.~Exclusion Criteria:~* A DSM-IV Axis I diagnosis other than schizophrenia or schizophreniform;~* Documented disease of the central nervous system that can interfere with the trial assessments including, but not limited to stroke, tumor, Parkinson's disease, Huntington's disease, seizure disorder, history of brain trauma resulting in significant impairment, chronic, infection;~* Acute, unstable and/or significant and untreated medical illness (e.g., infection, unstable diabetes, uncontrolled hypertension);~* A clinically significant ECG abnormality in the opinion of the investigator;~* Pregnant or breast-feeding female;~* Use of disallowed concomitant therapy;~* History of severe allergy or hypersensitivity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Celecoxib, immune adjustor (Type: EXPERIMENTAL): Celecoxib
- Placebo (Type: PLACEBO_COMPARATOR): Placebo looks like the active drug celecoxib, with the same dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Sodium Phosphate Tablets vs PEG for Bowel Cleansing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged from 18 to 75 years (included).~* Scheduled for a colonoscopy as an outpatient.~* Normal renal function~Exclusion Criteria:~* Having a disease or condition as follows:~  * repeated episodes of nausea and vomiting~ * abdominal pain due to severe infection or requiring surgery~ * clinically significant abnormal electrolytes values~ * congestive heart failure, unstable angina pectoris or recent myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass surgery within previous 3 months~ * known/suspected bowel obstruction, megacolon, ileus or intestinal perforation, or gastroparesis,~ * inflammatory bowel disease,~ * history of gastric stapling or bypass procedure or gastric retention~* Sodium phosphate preparation taken within the past three weeks prior to colonoscopy.~* Known allergy to any of the active ingredients or excipients of the study drugs.~* History of phenylketonuria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- polyethylene glycol (Type: ACTIVE_COMPARATOR): 4 Liters of PEG administered split in 2 doses
- oral sodium phosphate tablets (Type: EXPERIMENTAL): oral Sodium Phosphate tablets administered as 32 tablets (20+12) with 2 Liters of liquid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Footwear on the Clinical, Functional, and Biomechanical Aspects in Elderly Women With Knee Osteoarthritis (OA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Kellgren and Lawrence grade 2 or 3~* Being able to walk independently for at least 6 hours per day without the aid of canes or attendant to perform their activities of daily living~* Knee pain between 3 and 8 on the visual analogue scale~Exclusion Criteria:~* Previous history of surgery on knees, ankles and hips in the last 2 years~* Neurological disease~* BMI \> 35 kg/m2~* Difference in lower limb length \> 1 cm~* Prostheses and / or lower limb orthoses~* Having received steroid injections and hyaluronic acid intra-articular knee in previous periods of three and six months respectively~* Present at the knee joint instability (positive test results in the medial collateral ligament, lateral, anterior and posterior drawer)~* OA of the hip and / or ankle incapacitating or diagnosed OA in lower limbs and spine~* Inflammatory arthritis (eg. rheumatoid arthritis)~* Asymptomatic OA of one or both knees~* Dementia or inability to provide consistent information~* Introduction of Nonsteroidal Anti-inflammatory Drugs and analgesic medications 8 weeks before inclusion or change of dosage of the same after the inclusion~* Being under physiotherapy or acupuncture treatment~* Patients with an indication of prosthesis or orthosis~* Patients who are already using a flexible and non-heeled shoes for more than 25 hours per week (3 ½ hours per day) over the past 6 months

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): Daily use of the intervention Flexible footwear (Moleca®) for 6 months, for at least 42 hours/week (approximately 6 hours/day, 7 days/week). The Moleca® shoe (Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a low-cost women's double canvas, flexible, flat, walking shoe without heels, with a 5-mm anti-slip rubber sole and a 3-mm flat insole of ethylene vinyl acetate that provides only protection but no correction. The mean weight of the shoe is 0.172±0.019 kg (range 0.091 to 0.182 kg), depending on size. This minimalist footwear is commonly worn by the elderly of all social classes and its average cost is US$ 6.25.
- Control Group (Type: NO_INTERVENTION): During the intervention period, patients from the Control Group (CG) were instructed not to wear Flexible footwear (Moleca®) or other similar minimalist footwear. During everyday activities, the CG group was only permitted to wear a standard, neutral tennis shoe. At the end of the intervention period, all CG participants also received one pair of Moleca® shoes at no cost.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients who meet all of the following criteria are eligible for enrollment as study participants, including participants who:~* Subjects who were randomized to the placebo arm of protocol NA_00077852 Oral Immunotherapy for Induction of Tolerance in Peanut Allergic Children.~* Parent guardian must be able to understand and provide informed consent~* Peanut allergy, as defined by a reaction to a cumulative dose of ≤1000 mg of peanut protein during the End-of-Treatment food challenge from Protocol NA_00077852 Oral Immunotherapy for Induction of Tolerance in Peanut Allergic Children~Exclusion Criteria:~Patients who meet any of these criteria are not eligible for enrollment as study participants, including participants who:~* Inability or unwillingness of a parent guardian to give written informed consent or comply with study protocol~* History of severe anaphylaxis to peanut, defined by severe hypoxia, hypotension, neurological compromise, confusion, cardiovascular collapse, or loss of consciousness~* Significant chronic disease (other than asthma, rhinitis, or atopic dermatitis) requiring therapy; e.g., heart disease or cystic fibrosis which is judged by the investigator to have potential impact on study outcomes or safety.~* Severe or poorly controlled atopic dermatitis per investigator's discretion~* Past or current history of eosinophilic gastrointestinal disease~* Diagnosis of asthma that meets any of the following criteria:~  * Uncontrolled asthma (as per Global Initiative for Asthma \[GINA\] latest guidelines)~ * History of 2 or more systemic corticosteroid courses or 1 systemic course within the 3 previous months prior to visit 1 for treating wheezing~ * Prior intubation/mechanical ventilation for asthma~* Currently receiving β-blocking agents, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calcium channel blockers or tricyclic antidepressant therapy.~* Current participation in another clinical trial or participation in another clinical trial in the last 90 days

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Peanut Flour: Open label peanut OIT (Type: EXPERIMENTAL): This is an open label treatment for subjects who had previously received placebo treatment in a prior peanut OIT study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA ≥ 10\^4 IU/mL at screening~* Chronic HCV infection (≥ 6 months)~* Treatment experienced with a direct acting antiviral medication for HCV~* Use of protocol specified methods of contraception~Key Exclusion Criteria:~* Current or prior history of clinically significant illness that may interfere with participation in the study~* Screening ECG with clinically significant abnormalities~* Laboratory results outside of acceptable ranges at screening~* Pregnant or nursing female~* Chronic liver disease not caused by HCV~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL/VOX (Primary Study) (Type: EXPERIMENTAL): SOF/VEL/VOX for 12 weeks
- Placebo (Primary Study) (Type: EXPERIMENTAL): Placebo to match SOF/VEL/VOX for 12 weeks
- SOF/VEL/VOX (Deferred Treatment Substudy) (Type: EXPERIMENTAL): SOF/VEL/VOX for 12 weeks for eligible participants initially randomized to receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented colorectal adenocarcinoma~* Age over 18 years old~* Performance status (ECOG scale): 0-2~* Measurable or evaluable disease~* Patients can take food and drugs orally~* Adequate organ functions~* Life expectancy ≥ 3 months~* Patients should sign a written informed consent before study entry~Exclusion Criteria:~* Tumor type other than adenocarcinoma~* Second primary malignancy~* Prior systemic therapy (for instance, cytotoxic chemotherapy or active/passive immunotherapy) for advanced or metastatic colorectal cancer~* Adjuvant or neo-adjuvant treatment for non-metastatic (M0) disease has been completed within 6 months prior to initiation of study treatment.~* Prior radiotherapy was administered to target lesions selected for this study, or radiotherapy to the non-target lesions has been completed within 4 weeks before randomization.~* Presence of CNS metastasis~* Obvious peritoneal seeding or bowel obstruction disturbing oral intake~* Symptomatic peripheral neuropathy~* Major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from the effects of major surgery. The patient received curative operation or RFA for metastatic disease.~* Serious illness or medical conditions~* Receiving a concomitant treatment with drugs interacting with S-1, capecitabine or oxaliplatin, as follows;flucytosine, a fluorinated pyrimidine antifungal agent phenytoin warfarin etc.~* Received any investigational drug or agent/procedure, i.e. participation in another trial within 4 weeks before beginning treatment with study drug.~* Pregnant or lactating woman~* Women of child bearing potential not using a contraceptive method~* Sexually active fertile men not using effective birth control during medication of study drug and up to 6 months after completion of study drug if their partners are women of child-bearing potential~* Any patients judged by the investigator to be unfit to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S-1 and Oxaliplatin (Type: EXPERIMENTAL): S-1 and Oxaliplatin~S-1 : 80 mg/m2/day D1-14 Oxaliplatin : 130 mg/m2/day D1 Repeated every 3 weeks
- Capecitabine and Oxaliplatin (Type: ACTIVE_COMPARATOR): Capecitabine and Oxaliplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete